The silencing of FNDC1 inhibits the tumorigenesis of breast cancer cells via modulation of the PI3K/Akt signaling pathway

Yunwen,Chen; Shanshan,Gao; Zhifei,Ben; Saijun,Chen; Hua,Yin

doi:10.3892/mmr.2021.12118

The silencing of FNDC1 inhibits the tumorigenesis of breast cancer cells via modulation of the PI3K/Akt signaling pathway

Authors:
- Chen Yunwen
- Gao Shanshan
- Ben Zhifei
- Chen Saijun
- Yin Hua
View Affiliations

Affiliations: Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang 315010, P.R. China
Published online on: April 22, 2021 https://doi.org/10.3892/mmr.2021.12118
Article Number: 479
Copyright: © Yunwen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fibronectin type III domain‑containing protein 1 (FNDC1) is a protein that contains a major component of the structural domain of fibronectin. Although many studies have indicated that FNDC1 serves vital roles in the development of various diseases, the role of FNDC1 in the progression of breast cancer (BC) remains elusive. The aim of the present study was to investigate the biological functions of FNDC1 in BC cells and the associated mechanisms. The expression levels of FNDC1 in BC tissues and normal breast tissues were analyzed using The Cancer Genome Atlas database (TCGA). Kaplan‑Meier curves were mined from TCGA to examine the clinical prognostic significance of FNDC1 mRNA in patients with BC. The expression of FNDC1 was knocked down by transfection with shRNA in BC cells. Cell viability, colony formation ability, migration and invasion were assayed following the silencing of FNDC1 in BC cells. The expression of proteins was measured using a western blotting assay. The bioinformatic data indicated that the FNDC1 mRNA expression levels were significantly upregulated in BC tissues compared with normal breast tissues, and the high mRNA expression levels of FNDC1 were associated with a lower overall survival in patients with BC. The downregulation of FNDC1 inhibited the proliferation, colony formation, migration and invasion of BC cells. Investigation of the mechanisms revealed that the silencing of FNDC1 decreased the protein expression levels of MMPs and epithelial‑to‑mesenchymal markers. Furthermore, the silencing of FNDC1 led to the inactivation of the PI3K/Akt signaling pathway. FNDC1 was highly upregulated and acted as an oncogene in BC. Therefore, targeting FNDC1 may be a potential strategy for the treatment of BC.

View Figures

View References

1	DeSantis CE, Ma J, Goding Sauer A, Newman LA and Jemal A: Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
2	Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI
3	Khosravi-Shahi P, Cabezon-Gutierrez L and Custodio-Cabello S: Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol. 14:32–39. 2018. View Article : Google Scholar : PubMed/NCBI
4	Pankov R and Yamada KM: Fibronectin at a glance. J Cell Sci. 115:3861–3863. 2002. View Article : Google Scholar : PubMed/NCBI
5	Albrecht M, Renneberg H, Wennemuth G, Möschler O, Janssen M, Aumüller G and Konrad L: Fibronectin in human prostatic cells in vivo and in vitro: Expression, distribution, and pathological significance. Histochem Cell Biol. 112:51–61. 1999. View Article : Google Scholar : PubMed/NCBI
6	Fernandez-Garcia B, Eiro N, Marin L, González-Reyes S, González LO, Lamelas ML and Vizoso FJ: Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology. 64:512–522. 2014. View Article : Google Scholar : PubMed/NCBI
7	Anderegg U, Breitschwerdt K, Kohler MJ, Sticherling M, Haustein UF, Simon JC and Saalbach A: MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-beta and pro-inflammatory cytokines. Exp Dermatol. 14:709–718. 2005. View Article : Google Scholar : PubMed/NCBI
8	Das DK, Naidoo M, Ilboudo A, Park JY, Ali T, Krampis K, Robinson BD, Osborne JR and Ogunwobi OO: miR-1207-3p regulates the androgen receptor in prostate cancer via FNDC1/fibronectin. Exp Cell Res. 348:190–200. 2016. View Article : Google Scholar : PubMed/NCBI
9	Valster A, Tran NL, Nakada M, Berens ME, Chan AY and Symons M: Cell migration and invasion assays. Methods. 37:208–215. 2015. View Article : Google Scholar : PubMed/NCBI
10	Pijuan J, Barcelo C, Moreno DF, Maiques O, Sisó P, Marti RM, Macià A and Panosa A: In vitro cell migration, invasion, and adhesion assays: From cell imaging to data analysis. Front Cell Dev Biol. 7:1072019. View Article : Google Scholar : PubMed/NCBI
11	Liu YP, Chen WD, Li WN and Zhang M: Overexpression of FNDC1 relates to poor prognosis and its knockdown impairs cell invasion and migration in gastric cancer. Technol Cancer Res Treat. Jan 1–2019.(Epub ahead of print). doi: 10.1177/1533033819869928. View Article : Google Scholar
12	Wuensch T, Wizenty J, Quint J, Spitz W, Bosma M, Becker O, Adler A, Veltzke-Schlieker W, Stockmann M, Weiss S, et al: Expression analysis of fibronectin type III domain-containing (FNDC) genes in inflammatory bowel disease and colorectal cancer. Gastroenterol Res Pract. 2019:37841722019. View Article : Google Scholar : PubMed/NCBI
13	Reddy RB, Khora SS and Suresh A: Molecular prognosticators in clinically and pathologically distinct cohorts of head and neck squamous cell carcinoma-A meta-analysis approach. PLoS One. 14:e02189892019. View Article : Google Scholar : PubMed/NCBI
14	Zhong M and Zhang Y, Yuan F, Peng Y, Wu J, Yuan J, Zhu W and Zhang Y: High FNDC1 expression correlates with poor prognosis in gastric cancer. Exp Ther Med. 16:3847–3854. 2018.PubMed/NCBI
15	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
16	Clark AG and Vignjevic DM: Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol. 36:13–22. 2015. View Article : Google Scholar : PubMed/NCBI
17	Eble JA and Niland S: The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis. 36:171–198. 2019. View Article : Google Scholar : PubMed/NCBI
18	Hao S, Lv J, Yang Q, Wang A, Li Z, Guo Y and Zhang G: Identification of key genes and circular RNAs in human gastric cancer. Med Sci Monit. 25:2488–2504. 2019. View Article : Google Scholar : PubMed/NCBI
19	Chen Z, Tao Q, Qiao B and Zhang L: Silencing of LINC01116 suppresses the development of oral squamous cell carcinoma by up-regulating microRNA-136 to inhibit FN1. Cancer Manag Res. 11:6043–6059. 2019. View Article : Google Scholar : PubMed/NCBI
20	Liang H, Yu M, Yang R, Zhang L, Zhang L, Zhu D, Luo H, Hong Y, Yu T, Sun J, et al: A PTAL-miR-101-FN1 axis promotes EMT and invasion-metastasis in serous ovarian cancer. Mol Ther Oncolytics. 16:53–62. 2019. View Article : Google Scholar : PubMed/NCBI
21	Ren J, Niu G, Wang X, Song T, Hu Z and Ke C: Overexpression of FNDC1 in gastric cancer and its prognostic significance. J Cancer. 9:4586–4595. 2018. View Article : Google Scholar : PubMed/NCBI
22	Klein T and Bischoff R: Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 41:271–290. 2011. View Article : Google Scholar : PubMed/NCBI
23	Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R and Cher ML: Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst. 94:17–25. 2002. View Article : Google Scholar : PubMed/NCBI
24	Huang H: Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: Recent advances. Sensors (Basel). 18:32492018. View Article : Google Scholar : PubMed/NCBI
25	Kotiyal S and Bhattacharya S: Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun. 453:112–116. 2014. View Article : Google Scholar : PubMed/NCBI
26	Vincent CT and Fuxe J: EMT, inflammation and metastasis. Semin Cancer Biol. 47:168–169. 2017. View Article : Google Scholar : PubMed/NCBI
27	Aoki M and Fujishita T: Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 407:153–189. 2017.PubMed/NCBI
28	Sharma VR, Gupta GK and Sharma AK, Batra N, Sharma DK, Joshi A and Sharma AK: PI3K/Akt/mTOR intracellular pathway and breast cancer: Factors, mechanism and regulation. Curr Pharm Des. 23:1633–1638. 2017. View Article : Google Scholar : PubMed/NCBI
29	Guerrero-Zotano A, Mayer IA and Arteaga CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016. View Article : Google Scholar : PubMed/NCBI
30	Xiao Y, Wei R, Yuan Z, Lan X, Kuang J, Hu D, Song Y and Luo J: Rutin suppresses FNDC1 expression in bone marrow mesenchymal stem cells to inhibit postmenopausal osteoporosis. Am J Transl Res. 11:6680–6690. 2019.PubMed/NCBI